At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 296 enrolled
Drug / intervention
NKTR-181 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Enriched-Enrollment, Randomized-Withdrawal, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy, Tolerability, and Safety of NKTR-181 in Opioid-Naïve Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee
In Brief
A Phase 2 clinical trial evaluating NKTR-181 and Placebo for Osteoarthritis of the Knee. Completed, enrolled 296 participants across 34 sites.
Detailed Summary
NKTR-181 is being developed as an analgesic compound for the treatment of moderate to severe chronic pain - active as a mu agonist, but with inherent molecular properties designed to provide a unique clinical profile, including most notably, reduced CNS side effects and an attenuated attractiveness as a target of abuse.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoarthritis of the Knee
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartJun 2012
First PostedJun 2012
Primary CompletionAug 2013
Study CompletionSep 2013
TodayJul 2026
First PostedJun 14, 2012
Enrollment StartJun 1, 2012
Primary CompletionAug 1, 2013
Study CompletionSep 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 14.0 years ago
Interventions
NKTR-181drug
Placebodrug
Placebo dosing will be only in the double-blind randomization arm and will be identical in form to the Experimental NKTR-181